Literature DB >> 3947547

DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS).

S W Peters, R E Clark, T G Hoy, A Jacobs.   

Abstract

DNA distribution in bone marrow cells from 10 normal subjects and 34 patients with MDS (24 with refractory anaemia (RA) and 10 with excess blasts (RAEB] was determined by flow cytometry using a FACS III. DNA histograms were resolved into G0/1, S and G2/M compartments by fitting Gaussian distributions and the DNA content of G0/1 cells, expressed as DNA index (DI), was determined. In 19 MDS patients the DI was outside the normal range, those with RA tending to be hyperdiploid. Two patients with RAEB had a second G0/1 peak. In five cases of RA the number of cells in G0/1 was below the normal range and the mean value was significantly lower than normal for this group as a whole (P = 0 X 018). Eleven (RA) patients had a higher percentage of cells in G2/M than normal (P = 0 001). In RAEB patients there is a suggestion of increased numbers in G0/1 and a decrease in S phase and G2/M cells. All three of the deaths amongst RA patients and four out of the five deaths in RAEB patients since the beginning of this study were associated with an abnormal DI at the initial investigation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947547     DOI: 10.1111/j.1365-2141.1986.tb02927.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Assessment of DNA content and cell cycle distribution of erythroid and myeloid cells from bone marrow.

Authors:  J Hodgetts; T G Hoy; A Jacobs
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

2.  DNA index and karyotype analysis in myelodysplasia.

Authors:  T G Hoy; A D Geddes; A Jacobs
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

3.  Interphase ribosomal RNA cistron silver staining in refractory anaemias with and without excess blasts.

Authors:  N N Mamaev; G N Salogub; I B Nefedova
Journal:  Mol Pathol       Date:  1997-04

Review 4.  The role of apoptosis in the pathogenesis of the myelodysplastic syndromes.

Authors:  Jane E Parker; Ghulam J Mufti
Journal:  Int J Hematol       Date:  2001-06       Impact factor: 2.490

5.  Diagnostic and prognostic values of S-phase fraction and aneuploidy in patients with bone marrow aplasia.

Authors:  Payal Tripathi; Anil Kumar Tripathi; Ashutosh Kumar; Rizwan Ahmad; Anil Kumar Balapure; Achchhe Lal Vishwakerma
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

6.  Diagnostic and prognostic value of DNA image cytometry in myelodysplasia.

Authors:  W Auffermann; I Fohlmeister; A Böcking
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

7.  Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes.

Authors:  J Thiele; I Hoffmann; H P Bertsch; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis.

Authors:  David R Head; James W Jacobberger; Claudio Mosse; Madan Jagasia; William Dupont; Stacey Goodman; Leanne Flye; Andrew Shinar; Sara McClintock-Treep; Greg Stelzer; Robert Briggs; Keith Shults
Journal:  Bone Marrow Res       Date:  2011-06-07

Review 9.  Human preleukaemia: do we have a model?

Authors:  A Jacobs
Journal:  Br J Cancer       Date:  1987-01       Impact factor: 7.640

10.  The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.

Authors:  Sergio Matarraz; Cristina Teodosio; Carlos Fernandez; Manuel Albors; María Jara-Acevedo; Antonio López; María Gonzalez-Gonzalez; María Laura Gutierrez; Juan Flores-Montero; Carlos Cerveró; Marlies Pizarro-Perea; María Paz Garrastazul; Gonzalo Caballero; Oliver Gutierrez; Guy Daniel Mendez; Manuel González-Silva; Paula Laranjeira; Alberto Orfao
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.